Recursion Pharmaceuticals, Inc. RXRX Other Noncash Income (Expense)
Other Noncash Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other noncash income (expense)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other noncash income (expense) of -$1.67M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s other noncash income (expense) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other noncash income (expense) increased by 65.3% year-over-year, from -$4.82M to -$1.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s other noncash income (expense)?
- Over 2 years (2021 to 2024), Recursion Pharmaceuticals, Inc.'s other noncash income (expense) has grown at a 99.7% compound annual growth rate (CAGR), from -$4.1M to -$16.34M.
- What does other noncash income (expense) mean?
- This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.